NovAliX Enters into Multi-Target Integrated Drug Discovery Collaboration with Teijin Pharma
News Jan 12, 2012

NovAliX will initially use its protein biochemistry expertise in combination with its comprehensive biophysical technology platform. NovAliX will apply its proprietary Graffinity SPR-based screening technology for the identification of novel chemotypes, and then engage its native nano-MS technology for further characterization of selected small molecule hit structures.
This arrangement represents NovAliX’ first discovery collaboration with Teijin Pharma. Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments. Financial details of the transaction were not disclosed.
Stephan Jenn, President of NovAliX, stated, ”We are confident that this alliance will be very productive and are proud to be associated with Teijin’s technology-driven team. In this collaboration Teijin will have the opportunity to leverage the entire spectrum of our capabilities in biochemistry, biophysics and medicinal chemistry. For NovAliX this integrated collaboration represents a significant milestone as Teijin is the second Japanese pharmaceutical company to partner with us this year. This alliance underlines again the competitive edge of our scientific expertise and biophysical technologies as well as our commitment to serve the Japanese pharmaceutical research market that is strongly driven by science and innovation.”
RELATED ARTICLES
An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.
READ MOREThe days - or even weeks - spent waiting for the results of a cancer-screening test can feel like an eternity. Especially when early diagnosis and quick action are tied to better outcomes. Now, a new technique to analyze proteins expressed on cancer cells shows promise in more rapidly detecting these cell types.
READ MORELike what you just read? You can find similar content on the communities below.
Applied Sciences Drug DiscoveryTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019
26th Annual Cardiologists conference
Jul 10 - Jul 11, 2019